Clinical Trial Update: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation [Phase 1]

View source ↗

Summary

An ongoing Phase 1 trial evaluating CX-5461 in patients with advanced solid tumors harboring BRCA1/2, PALB2, or HRD mutations; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CX-5461 (CX-5461)

Snippet

Sponsor: Senhwa Biosciences, Inc. | Conditions: Advanced Solid Tumor | Phase 1 | Status: RECRUITING